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Introduction Several existing medications are being repurposed for treatment of COVID-19, including chloroquine
and hydroxychloroquine. The use of these medications has been associated with QT prolongation. Their use in patients
with COVID-19, magnifies the risk for development of heart arrhythmias.
Purpose The aim of this bibliographic research was to perform an analysis of existing clinical reports regarding effects 
of chloroquine and hydroxychloroquine used in patients with COVID-19 on myocardial repolarization, effects which 
can be measured on ECG as dispersion of QT interval and manifested clinically as heart arrhythmias. 
Material and methods: A three‐step approach was employed. Firstly, a search of clinical reports in HINARI and
PubMed using key words COVID-19 and QT dispersion was performed. Secondarily, selected articles were limited to
the English language and human studies. Finally, full texts of all the selected articles were reviewed in details and
points relevant to QT dispersion related to use of drugs were extracted. A number of 11 articles was selected for final
analysis. Full information regarding age of patients, dosage of drugs used, information about changes in QTc, clinical
outcomes were found in 7 articles, which analysis is presented in the table 1 and 2.
Conclusions:
Medications used in COVID-19 patients have the potential to affect electrophysiology of the heart and can be associated with QT dispersion on ECG. Giving importance to these ECG markers may have a significant contribution in decreasing drug-related arrhythmias
in this group of patients.
Chloroquine and hydroxychloroquine particularly when combined with azithromycin  increase the QTc in patients.
QTc prolongation is used as a surrogate of risk for torsades de pointes, but the relationship is imperfect. Risk generally increases when the QTc exceeds 500 ms.
The amount of QTc increase varies with drug dose, drug combination, sex, underlying heart disease in addition to COVID-19. 









Premature contractions producing short-long-short cycles
Impaired hepatic clearance of drugs
Diuretic use
Latent congenital LQTS polymorphisms








Changes in QTc interval
/maximal QTc
Complication related with QT interval
prolongation
Moussa Saleh,et.al USA 201 58.5 ± 9.1 years
M/F: 115/86
Ten patients (5.0%) received chloroquine
500 mg twice daily for
one day followed by 500 mg once daily
for four days, 191 (95.0%) patients
received hydroxychloroquine 400 mg
daily for one day followed by 200 mg
twice daily for four days.
119 (59.2%) patients
received azithromycin 500
mg by mouth or intravenous
daily for five days.
QTc enhanced by 19.33 ±
42.1 ms
Maximal QTc was 470.4±
45.0 ms.
Seven patients (3.5%) with average QTc of 504.4
± 39.5 ms required discontinuation of
medications.
There were 17 instances of new onset atrial
fibrillation, 7 patients had monomorphic
non-sustained ventricular tachycardia and one
patient had sustained, hemodynamically stable,
monomorphic ventricular tachycardia.
No arrhythmogenic deaths were reported.




All patients received hydroxychloroquine,
no information about dose.
53 (59%) patients received
azithromycin, no
information about dose
18 (20%) had posttreatment
QTc intervals of 500 ms or
more.
Ten patients (11%) stopped taking
hydroxychloroquine prior to day 5 of treatment
for QTc prolongation caused by premature
ventricular contractions and right bundle branch
block. One patient who had hydroxychloroquine
and azithromycin discontinued because of QTc
prolongation (499 ms) developed torsades
depointes 3 days later.
Jain et al. USA 524 68.2±15.2 years
M/F: 261/263
All patients received hydroxychloroquine,
no information about dose.
Only 3 patients received
azithromycin, no
information about dose.
20% of the patients showed
QT prolongation.
Average QTc in patients
with QT prolongation was
507.5±28.5ms
In 1/3 of the patients, treatment was
discontinued. None of the patients developed
torsades de pointes, and only 1 patient had
sustained ventricular tachycardia.
Bessiere et al. France 40 68 (58-74) years
M/F: 32/3
All patients received hydroxychloroquine
200 mg, twice a day, for 10 days.
18 patients received
azithromycin 250 mg, daily,
for 5 days.
Prolonged QTc was
observed in 14 patients
(36%) (10 with ΔQTc >60
milliseconds
and 7 with QTc ≥500
milliseconds) after a
duration of antiviral
treatment of 2 to 5 days.
17 patients had their drugs stopped because of
QTc increase and no patient developed TdP.
Chorin et al. USA 85 No data available All patients received hydroxychloroquine
400 mg twice daily on the first day,
followed by 200 mg twice daily.
All patients received
azithromycin which was
given at a dose of 500 mg
per day.
QT prolongation was
present in most treated
patients.
In 30% of patients QTc
increased by >40 ms, and
11% of patients had severe
prolongation (QTc >500
ms).
There were no torsades de pointes events
recorded for any patients, including those with a
severely prolonged QTc. Four patients died from
multi-organ failure, without evidence of
arrhythmia and without severe QTc prolongation.
Olivier Voisin et al. France 50 68 (53-81) years
M/F 28/22
All patients received hydroxychloroquine
600 mg/d for 10 days
All patients received
azithromycin 500 mg/d on
day 1 and 250 mg/d from
day 2 to day 5
38 patients (76%) presented
short-term modifications of
the QTc duration (>30 ms).
Treatment discontinuation was decided in 6
patients (12%), leading to QTc normalization in 5
of them. No deaths and no
cardiac arrhythmic events were observed in this
cohort.
Möhlmann J.E. et al. Netherlands 95 65(18–91) years
M/F: 63/32
All patients received chloroquine in a
loading dose of 600 mg followed by
300 mg twice daily (starting 12 h after the
loading dose), with a total treatment
duration of 5 days.
no Mean QTc was 479 (394–
564) ms.
Mean QTc prolongation was
35 (28–43).
22 patients (23%) had a
QTc interval exceeding
500 ms.
No torsade de pointes was observed.
Tab. 1. Risk factors for Torsades de Pointes associated with QTc > 500 ms
in patiets with COVID--19
Tab. 2. Clinical studies selected for analysis regarding effect of chloroquine or hydroxychloroquine on myocardial 
electrophysiology  and risk for arrhythmogenesis 
